SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 12, 2026

INSM

INSMED Inc
NEUTRAL
Impact 4/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $33.1M total
Actionable Insight • Neutral

The insider sales are routine post-vesting diversification by two C-suite executives following a massive earnings beat. The 0.11% of market cap sold is negligible. Focus on the bullish Q2 fundamentals, revenue beat, raised guidance, and narrowing losses, rather than this cluster. Monitor for any unplanned open-market selling by the CEO or CFO, which would be a more material signal.

DirectionNeutral
Confidencehigh
Horizondays

BRINSUPRI

▲ Bullish Named in this insider cluster
Impact
Phase
Approved
Time to market
Already approved and commercially launched in the US (August 2025), EU (November 2025), and Japan (August 2026)
Next catalyst
None dated

What to watchBRINSUPRI is already a commercial success with a blockbuster launch trajectory, but the stock has pulled back ~40% from its 52-week high of $212.75. With no imminent binary catalyst (the drug is already approved globally), the investment thesis hinges on continued commercial execution and pipeline progress from Insmed's other assets (TPIP, ARIKAYCE). Watch quarterly prescription trends and any label-expansion updates for brensocatib.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$126.33
T+0 close · Aug 12, 2026 · via day close
Latest settled
−11.08%
T+60 · $112.33
Vs SPY
−5.84%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $126.33entry
  2. T+1 · 3mo ago −2.05%α −1.85% · $123.74
  3. T+5 · 3mo ago −0.99%α +0.97% · $125.08
  4. T+20 · 2mo ago +2.44%α +4.19% · $129.41
  5. T+60 · 11d ago −11.08%α −5.84% · $112.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Insmed's COO and CMO sold a combined $33.1M in stock immediately following a blockbuster Q2 earnings beat (revenue $425.5M vs. $393.4M consensus) and raised guidance. The COO's $32M sale is the dominant event, executed after exercising options at much lower strike prices. While the earnings were strongly bullish, the insider sales are likely liquidity-driven post-vesting and are trivial relative to the $29B market cap (0.11%), making this a neutral cluster signal that does not offset the positive fundamental momentum.

Key Financial Metrics

Direction
selling
Total Value
$33.1M
Insiders
2

Key Facts

  • COO Roger Adsett sold 239,850 shares for $31.96M on 2026-08-10 after exercising options at $0-$30.46.
  • CMO Martina Flammer sold 27,173 shares total for $3.49M on 2026-08-06 after exercising options at $0-$25.83.
  • Total insider sales of $33.09M represent just 0.11% of INSM's $29B market cap.
  • Sales occurred 4-5 days after Q2 2026 earnings beat: revenue $425.5M vs. $393.4M consensus, raised FY2026 BRINSUPRI guidance to $1.25B-$1.4B.
  • All sales were preceded by option exercises at deep in-the-money strike prices, consistent with routine post-vesting diversification.

Financial Impact

Total insider sales of $33.09M, or 0.11% of market cap, immaterial relative to company size.

insider holdingsdilution

Risk Factors

  • Insider selling could accelerate if the stock continues to rally, creating near-term overhead supply.
  • Any future insider sales without corresponding option exercises would be a more bearish signal.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
97% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-INSM-1786568700959

Track record

24 reports on INSM

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago 144 Neutral 2/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
  2. Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
  3. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $122.88 +10.12% settles Nov 27
  4. Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $122.88 +30.67% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $122.88 +28.44% settles Nov 17
  6. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $122.88 +18.35% ▲ +8.43% +10.89% vs SPY
  7. Aug 19, 202612w ago Insider Cluster Neutral 4/10 Entry $125.08 to $120.00 Now $122.88 −1.76% ▼ −4.06% −4.19% vs SPY
  8. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Viewing Entry $126.33 to $129.41 Now $122.88 −2.73% ▲ +2.44% +4.19% vs SPY
  9. Aug 6, 202614w ago 8-K Bullish 8/10 Entry $132.55 to $126.68 Now $122.88 −7.30% ▼ −4.43% −5.03% vs SPY
  10. Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $122.88 +14.93% ▲ +17.63% +14.00% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens Wed (11h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026